CTNI-78. A PEDIATRIC AND YOUNG ADULT PHASE I DOSE ESCALATION SAFETY STUDY OF BXQ-350 FOR REFRACTORY SOLID AND CENTRAL NERVOUS SYSTEM TUMORS

MLA

Bhuvana A. Setty, et al. “Ctni-78. A Pediatric and Young Adult Phase I Dose Escalation Safety Study of Bxq-350 for Refractory Solid and Central Nervous System Tumors.” Neuro-Oncology, vol. 22, Nov. 2020, pp. ii60-ii61. EBSCOhost, https://doi.org/10.1093/neuonc/noaa215.244.

APA

Bhuvana A. Setty, Mariko DeWire, Rich Curry, Mohamed S. AbdelBaki, & Timothy P. Cripe. (2020). Ctni-78. A Pediatric and Young Adult Phase I Dose Escalation Safety Study of Bxq-350 for Refractory Solid and Central Nervous System Tumors. Neuro-Oncology, 22, ii60-ii61. https://doi.org/10.1093/neuonc/noaa215.244

Chicago

Bhuvana A. Setty, Mariko DeWire, Rich Curry, Mohamed S. AbdelBaki, and Timothy P. Cripe. 2020. “Ctni-78. A Pediatric and Young Adult Phase I Dose Escalation Safety Study of Bxq-350 for Refractory Solid and Central Nervous System Tumors.” Neuro-Oncology 22 (November): ii60-ii61. doi:10.1093/neuonc/noaa215.244.